PMID- 3546617
OWN - NLM
STAT- MEDLINE
DCOM- 19870422
LR  - 20170210
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 5
IP  - 3
DP  - 1987 Mar
TI  - Prevention of graft-versus-host disease in HLA-matched bone marrow 
      transplantation for malignant diseases: a multicentric study of 62 patients using 
      3-pan-T monoclonal antibodies and rabbit complement.
PG  - 426-35
AB  - In order to evaluate the effectiveness and reproducibility of T cell depletion in 
      human leukocyte antigen (HLA)-matched bone marrow graft to prevent graft-v-host 
      disease (GVHD), our multicentric study (nine different centers) investigated 62 
      consecutive patients with poor prognosis leukemia or hematosarcoma from June 1984 
      to November 1985. The data were updated October 1, 1986, and the mean follow-up 
      was 18 +/- 4.3 months. T cells were depleted with a combination of 3-pan-T cell 
      monoclonal antibodies (CD2 "D66"; CD5 "A50"; CD7 "I21") with a single incubation 
      of rabbit complement (C'). The average number of T cells infused was 0.66 X 10(6) 
      +/- 0.56/kg body weight. Twenty-six patients received chemoprophylaxis for GVHD, 
      16 received methotrexate, and ten received cyclosporin A. Only a single case of 
      severe (greater than grade II) GVHD was observed, yet the incidence of graft 
      failure was 19%. Factors that might have influenced the occurrence of graft 
      failure appear to be the lack of radiotherapy in the conditioning regimen; the 
      conditioning regimen itself (fractionated total body irradiation [TBI], 12 Gy, v 
      single dose is better than TBI, 10 Gy, but still not statistically significant); 
      and the age of the patients (high-risk after 30 years of age). In contrast, 
      neither the number of nucleated cells reinfused nor the level of T cell depletion 
      (provided the T cells were below critical numbers) seemed to have an influence, 
      nor did chemoprophylaxis for GVHD or splenectomy in chronic granulocytic leukemia 
      (CGL) patients. The survival of graft failure patients was very poor (one of 11; 
      survival at 15 months of the initial graft). Thus, our study demonstrates the 
      reproducibility and high effectiveness in preventing GVHD by immunodepletion of T 
      cells in a large-scale multicentric assay, in which compliance with the protocol 
      of immunodepletion was reasonably good. This study thus provides interesting 
      clues to overcoming graft rejection.
FAU - Racadot, E
AU  - Racadot E
FAU - Herve, P
AU  - Herve P
FAU - Beaujean, F
AU  - Beaujean F
FAU - Vernant, J P
AU  - Vernant JP
FAU - Flesch, M
AU  - Flesch M
FAU - Plouvier, E
AU  - Plouvier E
FAU - Andreu, G
AU  - Andreu G
FAU - Rio, B
AU  - Rio B
FAU - Philippe, N
AU  - Philippe N
FAU - Souillet, G
AU  - Souillet G
AU  - et al.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - 0 (Antibodies, Monoclonal)
RN  - 9007-36-7 (Complement System Proteins)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Antibodies, Monoclonal/*pharmacology
MH  - Bone Marrow/immunology
MH  - *Bone Marrow Transplantation
MH  - Child
MH  - Child, Preschool
MH  - Complement System Proteins/*pharmacology
MH  - Female
MH  - Graft Rejection
MH  - Graft vs Host Disease/*prevention & control
MH  - Humans
MH  - Infant
MH  - Leukemia/therapy
MH  - Lymphocyte Depletion
MH  - Male
MH  - Neoplasms/*therapy
MH  - Prognosis
MH  - T-Lymphocytes/immunology
EDAT- 1987/03/01 00:00
MHDA- 1987/03/01 00:01
CRDT- 1987/03/01 00:00
PHST- 1987/03/01 00:00 [pubmed]
PHST- 1987/03/01 00:01 [medline]
PHST- 1987/03/01 00:00 [entrez]
AID - 10.1200/JCO.1987.5.3.426 [doi]
PST - ppublish
SO  - J Clin Oncol. 1987 Mar;5(3):426-35. doi: 10.1200/JCO.1987.5.3.426.